Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
No completed, peer-reviewed human efficacy or long-term safety trial exists as of 2026
This initiative not only addresses the rising diabetes rates in Asia but also demonstrates Sanofi's strategic focus on tailoring products to meet local needs
FARXIGA 10 mg as monotherapy also provided statistically significant improvements in FPG and statistically significant reduction in body weight compared with metformin alone and was non-inferior to metformin XR monotherapy in lowering HbA1c
GLP-1 weight loss eligibility is determined by clinical criteria set by the FDA and medical guidelines, not a single BMI threshold
US$ 22.03
US$ 22.69
US$ 26.27
US$ 23.18
